Biologic therapies in psoriasis: a new therapeutic approach.
暂无分享,去创建一个
[1] S. Chimenti,et al. Safety and efficacy study on etanercept in patients with plaque psoriasis , 2005, The British journal of dermatology.
[2] A. Gottlieb,et al. Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.
[3] A. Gottlieb,et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.
[4] A. Finlay,et al. Patient‐reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial , 2005, The British journal of dermatology.
[5] Steven R. Cohen,et al. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. , 2006, Journal of the American Academy of Dermatology.
[6] A. Menter,et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. , 2005, Archives of dermatology.
[7] A. Gottlieb,et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. , 2005, Journal of the American Academy of Dermatology.
[8] R. Steinman,et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] N. Cox,et al. British Association of Dermatologists , 2001 .
[10] J. Koo,et al. Update on the mechanisms and efficacy of biological therapies for psoriasis. , 2005, Journal of dermatological science.
[11] A. Gottlieb,et al. A randomized trial of etanercept as monotherapy for psoriasis. , 2003, Archives of dermatology.
[12] L. Heinzerling,et al. Generalised Pustular Psoriasis Induced by Cyclosporin A Withdrawal Responding to the Tumour Necrosis Factor Alpha Inhibitor Etanercept , 2002, Dermatology.
[13] S. Feldman,et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial , 2005, The British journal of dermatology.
[14] A. Gottlieb,et al. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. , 2004, Journal of the American Academy of Dermatology.
[15] D. Gladman,et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.
[16] J. Bos,et al. Effects of etanercept on quality of life, fatigue, and depression in psoriasis , 2006, The Lancet.
[17] K. Joyce,et al. The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau. , 2005, Journal of drugs in dermatology : JDD.
[18] A. Gottlieb,et al. Psoriasis treatment: current and emerging directed therapies , 2005, Annals of the rheumatic diseases.
[19] F. Nestle,et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.
[20] U. Chaudhari,et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.
[21] M. Wener,et al. Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection , 2003, Annals of the rheumatic diseases.
[22] A. Finlay,et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 , 2005, The British journal of dermatology.
[23] F. Kerdel,et al. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type , 2002, International journal of dermatology.
[24] A. Nakanishi,et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.
[25] M. Lebwohl,et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.
[26] J. Grabbe,et al. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor‐α antibody (infliximab) , 2004, The British journal of dermatology.
[27] R. Gniadecki,et al. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. , 2004, Acta dermato-venereologica.